

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Hong Liu Examiner #: 77011 Date: 2/19/03
 Art Unit: 1624 Phone Number 306-5814 Serial Number: 09/548,081
 Mail Box and Bldg/Room Location: 4C01 Results Format Preferred (circle): PAPER DISK E-MAIL
4C12

If more than one search is submitted, please prioritize searches in order of need. *MEJ*

 Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species, or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____


Inventors (please provide full names): _____

Earliest Priority Filing Date: _____

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

RECEIVED
 FEB 19 2003
 (STIC)

Barb please!



see definitions of X, Y, A, Z in claim 1
see also provisos. Thanks!

Point of Contact:
 Barb O'Brien
 Technical Information Specialist
 STIC CM1 6A05 308-4291

STAFF USE ONLY

Searcher: Barb
 Searcher Phone #: _____
 Searcher Location: _____
 Date Searcher Picked Up: _____
 Date Completed: 2-24-03
 Searcher Prep & Review Time: 30
 Clerical Prep Time: _____
 Online Time: 22

Type of Search

NA Sequence (#) _____
 AA Sequence (#) _____
 Structure (#) 4
 Bibliographic _____
 Litigation _____
 Fulltext _____
 Patent Family _____
 Other _____

Vendors and cost where applicable


STN 401
 Dialog _____
 Questel/Orbit _____
 Dr.Link _____
 Lexis/Nexis _____
 Sequence Systems _____
 WWW/Internet _____
 Other (specify) _____

THIS PAGE BLANK (USPTO)

BioTech-Chem Library

Search Results

Feedback Form (Optional)



Scientific & Technical Information Center

The search results generated for your recent request are attached. If you have any questions or comments (compliments or complaints) about the scope or the results of the search, please contact *the BioTech-Chem searcher* who conducted the search *or contact*:

Mary Hale, Supervisor, 308-4258
CM-1 Room 1E01

Voluntary Results Feedback Form

➤ *I am an examiner in Workgroup:* (Example: 1610)

➤ *Relevant prior art found, search results used as follows:*

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
(journal articles, conference proceedings, new product announcements etc.)

➤ *Relevant prior art not found:*

- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Search results were not useful in determining patentability or understanding the invention.

Other Comments:

*This search didn't
pick up
X = NH.*

Drop off completed forms at the Circulation Desk CM-1, or send to Mary Hale, CM1-1E01 or mary.hale@uspto.gov

THIS PAGE BLANK (USPTO)

=> fil reg; d stat que 110; fil cap1; d que nos 111; fil uspatf; d que nos 112
 FILE 'REGISTRY' ENTERED AT 10:45:47 ON 24 FEB 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 21 FEB 2003 HIGHEST RN 493666-74-3
 DICTIONARY FILE UPDATES: 21 FEB 2003 HIGHEST RN 493666-74-3


















TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
 PROPERTIES for more information. See STNote 27, Searching Properties
 in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

L1 STR



VAR G1=CH2/12/14/16/19/SO2/21/24/30/27
 VAR G2=33/34/35/37/39/41/43/45/47/50
 NODE ATTRIBUTES:

NSPEC	IS R	AT	33
NSPEC	IS RC	AT	34
NSPEC	IS R	AT	36
NSPEC	IS RC	AT	38
NSPEC	IS R	AT	40
NSPEC	IS RC	AT	42
NSPEC	IS R	AT	44
NSPEC	IS RC	AT	46
NSPEC	IS R	AT	49
NSPEC	IS RC	AT	52

DEFAULT MLEVEL IS ATOM

= ring
 or chain node
 = chain node

*full file
 search done
 on this structure*

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 53

STEREO ATTRIBUTES: NONE

L3 STR



these 2 structures
"not"-ed out of answer set
(provisos)

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED



GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L4 STR



Cb @20 Ak @21

VAR G1=PH/14/15/19/20/21

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 20

CONNECT IS E1 RC AT 21

CONNECT IS E1 RC AT 23

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

ECOUNT IS M3-X8 C AT 20

GRAPH ATTRIBUTES:



















RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 23






STEREO ATTRIBUTES: NONE

L6 585 SEA FILE=REGISTRY SSS FUL L1 NOT (L3 OR L4)

L8 STR



Page 1-A



A = any non-hydrogen atom
= ring nodes & bonds

Page 2-A

VAR G1=CH2/12/14/16/19/SO2/21/24/30/27

VAR G2=33/34/35/37/39/41/43/45/47/50

VAR G3=CH2/54/56/58/61/63/67

NODE ATTRIBUTES:

NSPEC IS R AT 33

NSPEC IS RC AT 34

NSPEC IS R AT 36

NSPEC IS RC AT 38

NSPEC IS R AT 40

NSPEC IS RC AT 42

NSPEC IS R AT 44

NSPEC IS RC AT 46

NSPEC IS R AT 49

NSPEC IS RC AT 52

NSPEC IS R AT 66

NSPEC IS R AT 68

CONNECT IS E1 RC AT 57

CONNECT IS E1 RC AT 62

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 68

STEREO ATTRIBUTES: NONE

L10 165 SEA FILE=REGISTRY SUB=L6 SSS FUL L8

100.0% PROCESSED 585 ITERATIONS

SEARCH TIME: 00.00.01

165 ANSWERS

subset search
done on this structure

FILE 'CAPLUS' ENTERED AT 10:45:47 ON 24 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Feb 2003 VOL 138 ISS 9
FILE LAST UPDATED: 23 Feb 2003 (20030223/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

L1 STR
L3 STR
L4 STR
L6 585 SEA FILE=REGISTRY SSS FUL L1 NOT (L3 OR L4)
L8 STR
L10 165 SEA FILE=REGISTRY SUB=L6_SSS_FUL L8
L11 18 SEA FILE=CAPLUS ABB=ON L10

FILE 'USPATFULL' ENTERED AT 10:45:47 ON 24 FEB 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 20 Feb 2003 (20030220/PD)
FILE LAST UPDATED: 20 Feb 2003 (20030220/ED)
HIGHEST GRANTED PATENT NUMBER: US6523178
HIGHEST APPLICATION PUBLICATION NUMBER: US2003037360
CA INDEXING IS CURRENT THROUGH 20 Feb 2003 (20030220/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 20 Feb 2003 (20030220/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2002
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2002

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<

>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

L1 STR
L3 STR
L4 STR
L6 585 SEA FILE=REGISTRY SSS FUL L1 NOT (L3 OR L4)
L8 STR
L10 165 SEA FILE=REGISTRY SUB=L6 SSS FUL L8
L12 8 SEA FILE=USPATFULL ABB=ON L10

=> dup rem l11,l12

FILE 'CAPLUS' ENTERED AT 10:45:54 ON 24 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 10:45:54 ON 24 FEB 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L11
PROCESSING COMPLETED FOR L12


L14 25 DUP REM L11 L12 (1 DUPLICATE REMOVED)
ANSWERS '1-18' FROM FILE CAPLUS
ANSWERS '19-25' FROM FILE USPATFULL

~~=> d ibib abs hitstr 1-25; fil cao; d que nos l13; fil hom~~


L14 ANSWER 1 OF 25 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 1
ACCESSION NUMBER: 1980:146611 CAPLUS
DOCUMENT NUMBER: 92:146611
TITLE: Substituted 3,6-dihydro-1(2H)-pyridinylpropanols
INVENTOR(S): Hauck, Frederic P.; Fox, Rita T.; Watrous, John R.
PATENT ASSIGNEE(S): Squibb, E. R., and Sons, Inc., USA
SOURCE: U.S., 7 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4169200	A	19790925	US 1977-824378	19770815
US 4127579	A	19781128	US 1977-855038	19771125
CA 1113937	A1	19811208	CA 1978-299457	19780321
GB 1596357	A	19810826	GB 1978-12506	19780330
FR 2386528	A1	19781103	FR 1978-9535	19780331
FR 2386528	B1	19810724		
DE 2814799	A1	19781019	DE 1978-2814799	19780405
PRIORITY APPLN. INFO.:			US 1977-784888	19770405
			US 1977-824378	19770815
			US 1977-855038	19771125


GI



I



A=



B=


AB (Tetrahydropyridyl)isopropanols I [$n = 0, 1, 2$; $R =$ alkanoyl; $R_1 =$ x -phenyl-1,2,3,6-tetrahydro-1-pyridyl, A, x -styryl-1,2,3,6-tetrahydro-1-pyridyl, 4-(2-benzoxazolyl)-1,2,3,6-tetrahydro-1-pyridyl, 1,2,3,4-tetrahydroisoquinolin-2-yl, B], useful as antihypertensives (no data), were prepd. from the tetrahydropyridines and the resp. glycidyl-substituted bicyclic compds. Thus, a mixt. of 5-glycidyl-2,3,4a,8a-tetraacetoxydecalin, 4-phenyl-1,2,3,6-tetrahydropyridine, C_6H_6 , and EtOH was stirred .apprx.16h at 55-7.degree. to yield I ($n = 1$, $R = Ac$, $R_1 = 4$ -phenyl-1,2,3,6-tetrahydro-1-pyridyl).

IT 72717-36-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 72717-36-3 CAPLUS

CN 2,3,4a,8a-Naphthalenetetrol, octahydro-5-[2-hydroxy-3-(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propyl]- (9CI) (CA INDEX NAME)



114 ANSWER 2 OF 25 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:368319 CAPLUS

DOCUMENT NUMBER: 136:369716

TITLE: New use of 4,5,6,7-tetrahydroimidazo-[4,5-c]pyridine derivatives as inhibitors of semicarbazide-sensitive amine oxidase (SSAO) for treatment of, e.g., diabetic complications.

INVENTOR(S): Caldirola, Patrizia; Besencon, Olivier; Olsson, Rolf; Oehman, Johan

PATENT ASSIGNEE(S): Biovitrum AB, Swed.

SOURCE: PCT Int. Appl., 44 pp.


CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002038153	A1	20020516	WO 2001-SE2523	20011109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002014505	A5	20020521	AU 2002-14505	20011109
US 2002198189	A1	20021226	US 2001-45319	20011109
PRIORITY APPLN. INFO.:			SE 2000-4101	A 20001109
			US 2000-252156P	P 20001120
			WO 2001-SE2523	W 20011109

OTHER SOURCE(S): MARPAT 136:369716

GI



I



II

AB The invention relates to the use of title compds. I for the treatment or prophylaxis of SSAO-mediated complications, such as those of diabetes [wherein: R1 = H or CONHR5; R2 = H, COOR5, COR5, CONHR5, or C(S)NHR5; R3 = H, C1-8 alkyl, or (CH2)nAr; R4 = H, Ar, or C1-8 alkyl; and R5 = H, (CH2)nAr, (CH2)nOAr, C1-8 alkyl contg. 0-2 O atoms and optionally substituted with 0-5 halogen atoms, or a polyether chain having the formula (CH2)xO(CH2)yO(CH2)zCH3; n = 0-4; m = 0-2; x, y = 2-4; z = 0-3; Ar = (un)substituted Ph, 1-naphthyl, or 2-naphthyl, cinnamoyl, (un)substituted benzyl, 1,1-diphenylethyl, (un)substituted mono- or bicyclic heterocyclic ring (furyl, pyrrolyl, triazolyl, diazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyridyl, pyrimidyl, pyrazinyl, thienyl, imidazolyl, pyrazolyl, indolyl, quinolinyl, isoquinolinyl, benzofuryl, benzothienyl, benzoxadiazolyl), 2-, 3-, or 4-pyridyl, or a 5- to 7-membered (un)satd. heterocyclic ring each contg. 1-4 N/O/S atoms, with optional H, C1-6 alkyl, or CF3CO at ring N]. Approx. 40 compds. were prepd. For instance, cyclocondensation of histamine di-HCl with acetaldehyde in aq. MeOH in the presence of NaOH gave the invention compd. 4-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine (isolated as di-HCl salt), which reacted with benzyl chloroformate and K2CO3 in CHCl3 to give title compd. II. In tests against human umbilical arterial SSAO, using both H2O2 and aldehyde detection methods, compds. I at 12 .mu.M gave 1-97% inhibition.

IT **424837-38-7P**, Benzyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate **424837-55-8P**, 4-Phenyl-5-(phenoxyacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine trifluoroacetate

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; prepn. of tetrahydroimidazopyridine derivs. as SSAO inhibitors for treatment of diabetic complications)


RN 424837-38-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, phenylmethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-37-6


CMF C16 H19 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 424837-55-8 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-(phenoxyacetyl)-4-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-54-7


CMF C20 H19 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 424837-36-5P, Methyl 4-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-40-1P, Benzyl 4-phenyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate 424837-41-2P, Benzyl 4-benzyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-43-4P, Benzyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate 424837-45-6P, Methyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate 424837-47-8P, Methyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate 424837-49-0P, Methyl 4-phenyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate 424837-51-4P, 4-Ethyl-5-(phenoxyacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine trifluoroacetate 424837-53-6P, 4-Propyl-5-(phenoxyacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine trifluoroacetate 424837-57-0P, Cyclopentyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate 424837-59-2P, Cyclopentyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate 424837-61-6P, Cyclopentyl 4-phenyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate 424837-63-8P, 4-Fluorophenyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate 424837-65-0P, 4-Fluorophenyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate 424837-66-1P, 2-Methoxyethyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-67-2P, 2-Methoxyethyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-68-3P, 2-Methoxyethyl 4-phenyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-69-4P, Benzyl 4-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-70-7P, 4-Methyl-5-(phenoxyacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine 424837-71-8P, Allyl 4-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-72-9P, Allyl 4-ethyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-73-0P, Allyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-74-1P, 2,2,2-Trichloroethyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-75-2P, Allyl 4-benzyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-76-3P, 2,2,2-Trichloroethyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-77-4P, 2,2,2-Trichloroethyl 4-benzyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-78-5P, 4-Nitrobenzyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-79-6P, 4-Nitrobenzyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-85-4P, 4-Fluorophenyl 4-phenyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of tetrahydroimidazopyridine derivs. as SSAO inhibitors for treatment of diabetic complications)

RN 424837-36-5 CAPLUS


CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 424837-40-1 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-phenyl-, phenylmethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 424837-39-8
CMF C20 H19 N3 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 424837-41-2 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 424837-43-4 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-, phenylmethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 424837-42-3
CMF C17 H21 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 424837-45-6 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-44-5


CMF C10 H15 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 424837-47-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-46-7


CMF C11 H17 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 424837-49-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-phenyl-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-48-9


CMF C14 H15 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 424837-51-4 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine, 4-ethyl-4,5,6,7-tetrahydro-5-(phenoxyacetyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 424837-50-3
CMF C16 H19 N3 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 424837-53-6 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-(phenoxyacetyl)-4-propyl-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 424837-52-5
CMF C17 H21 N3 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 424837-57-0 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-,
cyclopentyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 424837-56-9
CMF C14 H21 N3 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 424837-59-2 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-, cyclopentyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 424837-58-1
CMF C15 H23 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 424837-61-6 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-phenyl-, cyclopentyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-60-5


CMF C18 H21 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 424837-63-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, 4-fluorophenyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-62-7


CMF C15 H16 F N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 424837-65-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-, 4-fluorophenyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-64-9


CMF C16 H18 F N3 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 424837-66-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 424837-67-2 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-phenyl-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 424837-68-3 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-phenyl-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 424837-69-4 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 424837-70-7 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-4-methyl-5-(phenoxyacetyl)- (9CI) (CA INDEX NAME)




RN 424837-71-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-methyl-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 424837-72-9 CAPLUS


CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 424837-73-0 CAPLUS


CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-, 2-propenyl ester (9CI) (CA INDEX NAME)

2-propenyl ester (9CI) (CA INDEX NAME)




RN 424837-74-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)




RN 424837-75-2 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-(phenylmethyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 424837-76-3 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)




RN 424837-77-4 CAPLUS


CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-(phenylmethyl)-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)



RN 424837-78-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-,
(4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

RN 424837-79-6 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-,
(4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)


RN 424837-85-4 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-phenyl-,
4-fluorophenyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-84-3


CMF C19 H16 F N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

✓ L14 ANSWER 3 OF 25 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:525970 CAPLUS

DOCUMENT NUMBER: 135:117216
TITLE: Macrocyclic peptidomimetic inhibitors of
prenyl-protein transferase for inhibiting prenylation
of Ras oncoprotein
INVENTOR(S): Desolms, S. Jane; Shaw, Anthony W.
PATENT ASSIGNEE(S): Merck + Co., Inc., USA
SOURCE: PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001051128	A1	20010719	WO 2001-US635	20010109
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

US 6350755 B1 20020226 US 2001-757218 20010109

PRIORITY APPLN. INFO.: US 2000-175703P P-20000112

OTHER SOURCE(S): MARPAT 135:117216

AB The present invention is directed to peptidomimetic macrocyclic compds. which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compns. contg. the compds. of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.


IT 350687-92-2P 350687-93-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(macrocyclic peptidomimetic inhibitors of prenyl-protein transferase for inhibiting prenylation of Ras oncoprotein)


RN 350687-92-2 CAPLUS

CN 3H-Imidazo[4,5-c]pyridine, 4-(4-cyano-3-fluorophenyl)-4,5,6,7-tetrahydro-5-[3-[[[(3-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 350687-93-3 CAPLUS

CN 3H-Imidazo[4,5-c]pyridine, 4-(4-cyano-3-fluorophenyl)-4,5,6,7-tetrahydro-5-[3-[[[(3-hydroxyphenyl)sulfonyl]amino]-1-oxopropyl]-3-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

~~L14~~ ANSWER 4 OF 25 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:494661 CAPLUS

DOCUMENT NUMBER: 135:242187

TITLE: Synthesis of phenothiazine derivatives of spinaceamine and 2-azaspinaceamine

AUTHOR(S): Yutilov, Yu. M.; Smolyar, N. N.; Abramyan, M. G.; Tyurenkov, I. N.

CORPORATE SOURCE: Litvinenko Institute of Organic Chemistry, National Academy of Sciences of the Republic of Ukraine, Donetsk, Ukraine

SOURCE: Pharmaceutical Chemistry Journal (Translation of Khimiko-Farmatsevticheskii Zhurnal) (2001), 35(1), 15-17

CODEN: PCJOAU; ISSN: 0091-150X

PUBLISHER: Consultants Bureau

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:242187


AB Triazolo[4,5-c]pyridines and imidazo[4,5-c]pyridines are added to 2-chloro-10-(.beta.-chloropropionyl)phenothiazine, then reduced to give the spinaceamine and azaspinaceamine phenothiazine derivs.

IT **360794-61-2P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of phenothiazine derivs. of spinaceamine and 2-azaspinaceamine)

RN 360794-61-2 CAPLUS

CN 10H-Phenothiazine, 2-chloro-10-[1-oxo-3-(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 5 OF 25 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:756706 CAPLUS

DOCUMENT NUMBER: 133:321882

TITLE: Preparation of substituted fused imidazoles for treatment and/or prevention of diseases and disorders

INVENTOR(S): related to the histamine H3 receptor
Dorwald, Florencio Zaragoza; Andersen, Knud Erik;
Jorgensen, Tine Krogh; Peschke, Bernd; Wulff, Birgitte
Schjellerup; Pettersson, Ingrid; Rudolf, Klaus;
Stenkamp, Dirk; Hurnaus, Rudolf; Muller, Stephan
Georg; Krist, Bernd

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.; Boehringer Ingelheim
International, G.m.b.H.

SOURCE: PCT Int. Appl., 169 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

applicant

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000063208	A1	20001026	WO 2000-DK179	20000413
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1173438	A1	20020123	EP 2000-918714	20000413
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002542245	T2	20021210	JP 2000-612298	20000413
PRIORITY APPLN. INFO.:			DK 1999-508	A 19990416
			DK 1999-1345	A 19990922
			DK 2000-42	A 20000112
			WO 2000-DK179	W 20000413
OTHER SOURCE(S):	MARPAT 133:321882			
GI				



AB The title compds. [I; R1 = H, a functional group which can be converted to H in vivo; R2 = H, alkyl, halo, etc.; R3-R6 = H, CO2H, alkoxycarbonyl, etc.; m, n, p, q = 0-2; X = a bond, CH2, CO, etc.; Y = a bond, O, NR12 (R12 = H, alkyl, aryl, etc.); A = a bond, alkylene, alkenylene, etc.; Z = R13, OR13, SR13, etc. (R13 = H, alkyl, aryl, etc.)], useful for the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor (more particularly, useful for the treatment and/or prevention of diseases and disorders, in which an interaction with the histamine H3 receptor is beneficial), were prepd. and formulated. E.g., treatment of 5-cyclohexylpentanoic acid with carbonyldiimidazole in DCM followed by addn. of 4,5,6,7-tetrahydroimidazo[4,5-c]pyridine in DCM afforded 24% II. Compds. I are effective at 0.05-10 mg/kg/day.

IT 303019-79-6P 303019-80-9P 303019-81-0P
303019-82-1P 303019-83-2P 303019-84-3P
303019-86-5P 303019-87-6P 303019-89-8P
303020-01-1P 303020-03-3P 303020-05-5P
303020-07-7P 303020-09-9P 303020-11-3P
303020-13-5P 303020-15-7P 303020-17-9P
303020-19-1P 303020-21-5P 303020-23-7P
303020-25-9P 303020-27-1P 303020-29-3P
303020-31-7P 303020-33-9P 303020-35-1P
303020-37-3P 303020-39-5P 303020-41-9P
303020-43-1P 303020-45-3P 303020-47-5P
303020-49-7P 303020-51-1P 303020-53-3P
303020-55-5P 303020-57-7P 303020-59-9P
303020-61-3P 303020-63-5P 303020-64-6P
303020-65-7P 303020-66-8P 303020-67-9P
303020-68-0P 303020-69-1P 303020-70-4P
303020-71-5P 303020-72-6P 303020-74-8P
303020-75-9P 303020-77-1P 303020-79-3P
303020-81-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of substituted fused imidazoles for treatment and/or prevention of diseases and disorders related to the histamine H3 receptor)


RN 303019-79-6 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine, 5-(3-cyclohexyl-1-oxopropyl)-4,5,6,7-tetrahydro-4,4-dimethyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303019-78-5


CMF C17 H27 N3 O




CM 2

CRN 144-62-7


CMF C2 H2 O4




RN 303019-80-9 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine, 5-(5-cyclohexyl-1-oxopentyl)-4,5,6,7-tetrahydro-
 (9CI) (CA INDEX NAME)




RN 303019-81-0 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-(1-oxo-6-phenylhexyl)-
 (9CI) (CA INDEX NAME)




RN 303019-82-1 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine, 5-(3-cyclohexyl-1-oxopropyl)-4,5,6,7-tetrahydro-
 (9CI) (CA INDEX NAME)



RN 303019-83-2 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine, 5-[3-(4-fluorophenyl)-1-oxopropyl]-4,5,6,7-tetrahydro-4-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 303019-84-3 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-(1-oxo-3,3-diphenylpropyl)-
 (9CI) (CA INDEX NAME)




RN 303019-86-5 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine, 5-(3-cyclohexyl-1-oxopropyl)-4-ethyl-4,5,6,7-tetrahydro-4-methyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303019-85-4


CMF C18 H29 N3 O



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 303019-87-6 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine, 5-[3-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-oxopropyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)




RN 303019-89-8 CAPLUS

CN Spiro[cyclobutane-1,4'-[4H]imidazo[4,5-c]pyridine], 1',5',6',7'-tetrahydro-5'-(3-cyclohexyl-1-oxopropyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303019-88-7


CMF C18 H27 N3 O




CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 303020-01-1 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine, 5-(cyclohexylacetyl)-4,5,6,7-tetrahydro- (9CI)
(CA INDEX NAME)


RN 303020-03-3 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
[4-(1,1-dimethylethyl)phenyl]methyl ester, ethanedioate (1:1) (9CI) (CA
INDEX NAME)

CM 1

CRN 303020-02-2


CMF C18 H23 N3 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 303020-05-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
(2,3-dimethylphenyl)methyl ester, ethanedioate (1:1) (9CI) (CA INDEX
NAME)

CM 1

CRN 303020-04-4


CMF C16 H19 N3 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 303020-07-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
2-phenylbutyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-06-6


CMF C17 H21 N3 O2



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 303020-09-9 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
(3-methoxyphenyl)methyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 303020-08-8
CMF C15 H17 N3 O3



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 303020-11-3 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
cyclopentylmethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 303020-10-2
CMF C13 H19 N3 O2



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 303020-13-5 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
(3-methylphenyl)methyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 303020-12-4
CMF C15 H17 N3 O2



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 303020-15-7 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
(2-methylphenyl)methyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 303020-14-6
CMF C15 H17 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 303020-17-9 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
2-(2-methoxyphenyl)ethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-16-8


CMF C16 H19 N3 O3



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 303020-19-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
2-(3-methylphenyl)ethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-18-0


CMF C16 H19 N3 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 303020-21-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl ester, ethanedioate (1:1) (9CI) (CA
INDEX NAME)


CM 1

CRN 303020-20-4
CMF C18 H25 N3 O2



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 303020-23-7 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
(3,4-dimethylphenyl)methyl ester, ethanedioate (1:1) (9CI) (CA INDEX
NAME)


CM 1

CRN 303020-22-6
CMF C16 H19 N3 O2



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 303020-25-9 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
3-cyclohexen-1-ylmethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 303020-24-8
CMF C14 H19 N3 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 303020-27-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
(2,4-dimethylphenyl)methyl ester, ethanedioate (1:1) (9CI) (CA INDEX
NAME)

CM 1

CRN 303020-26-0


CMF C16 H19 N3 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 303020-29-3 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
2-(2-methylphenyl)ethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-28-2


CMF C16 H19 N3 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 303020-31-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
1-naphthalenylmethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-30-6


CMF C18 H17 N3 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 303020-33-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
[4-(1-methylethyl)phenyl]methyl ester, ethanedioate (1:1) (9CI) (CA INDEX
NAME)


CM 1

CRN 303020-32-8
CMF C17 H21 N3 O2



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 303020-35-1 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
2-naphthalenylmethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 303020-34-0
CMF C18 H17 N3 O2



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 303020-37-3 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
(2-methyl[1,1'-biphenyl]-3-yl)methyl ester, ethanedioate (1:1) (9CI) (CA
INDEX NAME)

CM 1


CRN 303020-36-2
CMF C21 H21 N3 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 303020-39-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
(4-ethylphenyl)methyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-38-4


CMF C16 H19 N3 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 303020-41-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
2-thienylmethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-40-8


CMF C12 H13 N3 O2 S



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 303020-43-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
2-(2-thienyl)ethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-42-0


CMF C13 H15 N3 O2 S



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 303020-45-3 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
2-(3-thienyl)ethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-44-2


CMF C13 H15 N3 O2 S



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 303020-47-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
(4-methoxy-2,3-dimethylphenyl)methyl ester, ethanedioate (1:1) (9CI) (CA
INDEX NAME)

CM 1

CRN 303020-46-4


CMF C17 H21 N3 O3



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 303020-49-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-
(trifluoromethyl)-, phenylmethyl ester, ethanedioate (1:1) (9CI) (CA
INDEX NAME)

CM 1

CRN 303020-48-6


CMF C15 H14 F3 N3 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 303020-51-1 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, 2-cyclohexylethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-50-0


CMF C15 H23 N3 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 303020-53-3 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-, cyclohexylmethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-52-2


CMF C14 H21 N3 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 303020-55-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
(2-chlorophenyl)methyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-54-4


CMF C14 H14 Cl N3 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 303020-57-7 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
[2-(trifluoromethyl)phenyl]methyl ester, ethanedioate (1:1) (9CI) (CA
INDEX NAME)

CM 1

CRN 303020-56-6


CMF C15 H14 F3 N3 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 303020-59-9 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-,
1-phenylethyl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-58-8


CMF C15 H17 N3 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 303020-61-3 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-[[4-(phenylmethyl)-1-piperidiny]carbonyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-60-2


CMF C19 H24 N4 O



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 303020-63-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxamide, 1,4,6,7-tetrahydro-N-methyl-N-(phenylmethyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-62-4


CMF C15 H18 N4 O



CM 2


CRN 144-62-7

CMF C2 H2 O4




RN 303020-64-6 CAPLUS


CN Isoquinoline, 1,2,3,4-tetrahydro-2-[(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)carbonyl]- (9CI) (CA INDEX NAME)



RN 303020-65-7 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 5-(3,3-dimethyl-1-oxobutyl)-4,5,6,7-tetrahydro-
(9CI) (CA INDEX NAME)




RN 303020-66-8 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-(1-oxo-3-phenyl-2-propynyl)- (9CI) (CA INDEX NAME)



RN 303020-67-9 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-(1-oxo-3-phenyl-2-propynyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 303020-66-8
CMF C15 H13 N3 O




CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 303020-68-0 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 5-[(2E)-3-[4-(1,1-dimethylethyl)phenyl]-1-oxo-2-propenyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 303020-69-1 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 5-[(2E)-3-[4-(1,1-dimethylethyl)phenyl]-1-oxo-2-propenyl]-4,5,6,7-tetrahydro-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 303020-68-0
CMF C19 H23 N3 O

Double bond geometry as shown.




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 303020-70-4 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 5-(bicyclo[2.2.1]hept-2-ylacetyl)-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 303020-71-5 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 5-(bicyclo[2.2.1]hept-2-ylacetyl)-4,5,6,7-tetrahydro-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 303020-70-4
CMF C15 H21 N3 O




CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 303020-72-6 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-(4-pentylbenzoyl)-,
monohydrochloride (9CI) (CA INDEX NAME)

● HCl


RN 303020-74-8 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-(4-pentylbenzoyl)-,
ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-73-7


CMF C18 H23 N3 O




CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 303020-75-9 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-[4-(trifluoromethoxy)benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 303020-77-1 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-[4-(trifluoromethyl)benzoyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 303020-76-0
CMF C14 H12 F3 N3 O



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 303020-79-3 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-[4-(2-methylpropyl)benzoyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 303020-78-2
CMF C17 H21 N3 O



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 303020-81-7 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine, 5-(4-chlorobenzoyl)-4,5,6,7-tetrahydro-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 303020-80-6


CMF C13 H12 Cl N3 O



CM 2

CRN 144-62-7

CMF C2 H2 O4



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

114 ANSWER 6 OF 25 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:654406 CAPLUS

DOCUMENT NUMBER: 133:222577



TITLE: Preparation of aminoalkoxyacetophenone, 1-alkenoyl-2-aminoalkoxybenzene derivatives and analogs for the treatment of inflammation and osteoporosis

INVENTOR(S): Ohara, Takashi; Shimano, Masanao; Nagahara, Michiko; Ichikawa, Kiyonoshin; Awa, Takao; Nogimori, Katsumi

PATENT ASSIGNEE(S): Kaken Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 24 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000256286	A2	20000919	JP 1999-65636	19990311
PRIORITY APPLN. INFO.:			JP 1999-65636	19990311
OTHER SOURCE(S):	MARPAT 133:222577			
GI				



AB The title compds. I [ring A = arom. ring, etc.; R¹ = H, alkyl, etc.; R² = H, halo, etc.; B = (un)substituted alkylene, etc.; R³, R⁴ = H, (un)substituted alkyl, etc.; X = carbonyl, etc.; Y = O, etc.] are prepd. An in vitro assay using macrophages treated with LPS was performed: in the presence of the title compd. II at 10⁻⁶ M, the amt. of interleukin 6 secreted was 15415.+-1360 pg, vs. 23474.+-2404 pg in controls. Formulations are given.


IT **292154-83-7P 292154-84-8P 292154-85-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aminoalkoxyacetophenone and 1-alkenyl-2-aminoalkoxybenzene derivs. for treatment of inflammation and osteoporosis)


RN 292154-83-7 CAPLUS

CN 2-Propen-1-one, 3-(2-furanyl)-1-[2-[3-(3,4,6,7-tetrahydro-3-methyl-5H-imidazo[4,5-c]pyridin-5-yl)propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 292154-84-8 CAPLUS

CN 2-Propen-1-one, 3-(2-furanyl)-1-[2-[3-[3,4,6,7-tetrahydro-3-(phenylmethyl)-5H-imidazo[4,5-c]pyridin-5-yl]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 292154-85-9 CAPLUS

CN 2-Propen-1-one, 3-(2-furanyl)-1-[2-[3-(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)propoxy]phenyl]- (9CI) (CA INDEX NAME)



L14 ANSWER 7 OF 25 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:460401 CAPLUS

DOCUMENT NUMBER: 131:87906

TITLE: Preparation of tetrahydrobenzindole derivatives for treatment and prevention of diseases caused by abnormality in serotonin regulatory system

INVENTOR(S): Kikuchi, Chika; Ando, Takashi; Fuji, Kazuyuki; Okuno, Masayo; Satoh, Eriko; Shiiyama, Masako; Ushiroda, Osamu; Koyama, Masao; Hiranuma, Toyokazu

PATENT ASSIGNEE(S): Meiji Seika Kaisha, Ltd., Japan

SOURCE: PCT Int. Appl., 139 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9933804	A1	19990708	WO 1998-JP5827	19981222
W: CA, CN, JP, KR, NO, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 11189585	A2	19990713	JP 1997-358381	19971225
CA 2316388	AA	19990708	CA 1998-2316388	19981222
EP 1057814	A1	20001206	EP 1998-961493	19981222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
NO 2000003285	A	20000823	NO 2000-3285	20000622
US 6498251	B1	20021224	US 2001-582416	20010308

PRIORITY APPLN. INFO.:

JP 1997-358380	A	19971225
JP 1997-358381	A	19971225
JP 1998-85913	A	19980331
JP 1998-136872	A	19980519
JP 1998-229709	A	19980814

JP 1998-319336 A 19981110
WO 1998-JP5827 W 19981222

OTHER SOURCE(S): MARPAT 131:87906
GI




AB Compds. I [.alpha. = Q1, etc.; R1 = H, alkyl, etc.; R2 = H, halo, etc.; X = NR10, etc. (R10 = H, etc.); n = 2 to 6; R3 = H, etc.] are prepd. Thus, 2a-(4-bromobutyl)-2a,3,4,5-tetrahydro-1H-benz[cd]indol-2-one 150 mg was reacted with 2,3,4,9-tetrahydro-1H-pyrido[2,4-b]indole 168 mg to give 2a-[4-(2,3,4,9-tetrahydro-1H-pyrido[2,4-b]indole)butyl]-2a,3,4,5-tetrahydro-1H-benz[cd]indol-2-one 73 mg, showing Ki values 227 nM in affinity test to 5-HT7 receptor, and 7 nM in affinity test to 5-HT2 receptor.

IT 230301-50-5P 230301-52-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tetrahydrobenzindole derivs. for treatment and prevention of diseases caused by abnormality in serotonin regulatory system)


RN 230301-50-5 CAPLUS

CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butyl]- (9CI) (CA INDEX NAME)



RN 230301-52-7 CAPLUS

CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 8 OF 25 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:612094 CAPLUS

DOCUMENT NUMBER: 129:245172

TITLE: Preparation of 4,4-difluoro-2,3,4,5-tetrahydro-1H-1-benzazepine derivatives as oxytocin antagonists

INVENTOR(S): Matsuhisa, Akira; Murakami, Takeshi; Sakuda, Shuichi; Kawano, Noriyuki; Shibasaki, Kumiko; Tanaka, Akihiro
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9839325	A1	19980911	WO 1998-JP916	19980305
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9861204	A1	19980922	AU 1998-61204	19980305
EP 987264	A1	20000322	EP 1998-905779	19980305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
US 6340678	B1	20020122	US 1999-380683	19990902
PRIORITY APPLN. INFO.: JP 1997-52163 A 19970306				
WO 1998-JP916 W 19980305				

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title 4,4-Difluoro-2,3,4,5-tetrahydro-1H-1-benzazepine derivs. represented by formula (I) or salts thereof (wherein A is 5-membered heteroarylene; B is optionally substituted aryl or 5- or 6-membered heteroaryl; D is carbonyl or lower alkylene; R1 is -NR3R4, -O-(lower alkyl) or OH; R2 is optionally halogenated lower alkyl, -O-(lower alkyl), -S-(lower alkyl) or -CO-(lower alkyl); R3 and R4 are each independently hydrogen, lower alkyl or the like; and n is 0, 1 or 2). The above compds.

exhibit the oxytocin antagonism and are effective in inhibiting threatened premature birth or abortion, or precesarean birth and useful as remedies for dysmenorrhea and so on (no data). Thus, 1H-benzoazepin-5-ylideneacetic acid deriv. (II; R = OH) was condensed with 2-(piperazin-1-yl)ethanol using DCC at room temp. for 18 h to give II (R = Q).


IT 213021-71-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of difluorotetrahydrobenzazepine derivs. as oxytocin antagonists)

RN 213021-71-7 CAPLUS

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-oxo-2-(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethylidene]-, monohydrochloride, (5Z)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



● HCl

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

✓
D14 ANSWER 9 OF 25 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:484944 CAPLUS

DOCUMENT NUMBER: 129:109089

TITLE: Preparation of oxopyridinylmethylimidazolylmethylbenzo nitriles and related compounds as inhibitors of farnesyl-protein transferase.

INVENTOR(S): Young, Steven D.; Anthony, Neville J.; Graham, Samuel L.; Tran, Lekhanh O.; Bell, Ian M.; Desolms, S. Jane; Gomez, Robert P.; Kuo, Michelle Sparks; Lumma, William C., Jr.; Perlow, Debra S.; Shaw, Anthony W.; Wai, John S.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA; et al.

SOURCE: PCT Int. Appl., 220 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9829119	A1	19980709	WO 1997-US23893	19971222
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9857195	A1	19980731	AU 1998-57195	19971222
US 5939439	A	19990817	US 1997-995744	19971222
EP 951285	A1	19991027	EP 1997-953451	19971222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2001507699	T2	20010612	JP 1998-530217	19971222
US 6077853	A	20000620	US 1999-300910	19990428
PRIORITY APPLN. INFO.:			US 1996-33990P	P 19961230
			GB 1997-2211	A 19970204
			US 1997-995744	A3 19971222
			WO 1997-US23893	W 19971222
OTHER SOURCE(S): MARPAT 129:109089				
AB	(R8)rVA1[C(R1)2]nA2[C(R1)2]n[W(R9)q]t[C(R2)2]pX[C(R2)2]pYR3R4R5QR6aR6bR6cR6dR6e [Q = 4-7 membered N-heterocyclacyl; Y = 5-7 membered (hetero)cyclyl; R1, R2 = H, aryl, heterocyclyl, cycloalkyl, alkenyl, alkynyl, (substituted) alkyl, etc.; R3-R5, R6a-R6e = H, (substituted) aryl, heterocyclyl, alkyl, cycloalkyl, alkenyl, alkynyl, halo, perfluoroalkyl, etc.; adjacent R6a-R6e = CH:CHCH:CH, (CH2)3-4, CH:CHCH2, etc.; R8 = H, (substituted) alkyl, aryl, heterocyclyl, cycloalkyl, alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, etc.; R9 = H, (substituted) alkyl, alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, etc.; A1, A2 = bond, CH:CHV = H, heterocyclyl, aryl, alkyl, etc. W = heterocyclyl; X = bond, CH:CH, O, CO, S, SO, SO2, CO2, imino, etc.; n, p = 0-4; q = 0-3; r = 0-5; t = 0, 1], were prepd. Thus, 4-(2-oxo-2H-pyridin-1-yl)benzyl bromide (prepn. given) and 4-(1-trityl-1H-imidazol-4-ylmethyl)benzonitrile were refluxed in MeCN to give a residue which was refluxed 2 h in MeOH to give 4-[3-[4-(2-oxo-2H-pyridin-1-yl)benzyl]-3H-imidazol-4-ylmethyl]benzonitrile. Title compds. inhibited ras farnesyl transferase with IC50<50 .mu.M.			
IT	210037-52-8P 210037-53-9P			
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
(prepn. of oxypyridinylmethylimidazolylmethylbenzonitriles and related compds. as inhibitors of farnesyl-protein transferase)				
RN	210037-52-8 CAPLUS			
CN	5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-(4-cyanophenyl)-1,4,6,7-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)			



RN 210037-53-9 CAPLUS
 CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 3-[(5-chloro-2-oxo[1(2H),2'-bipyridin]-5'-yl)methyl]-4-(4-cyanophenyl)-3,4,6,7-tetrahydro-,

1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 10 OF 25 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:85131 CAPLUS

DOCUMENT NUMBER: 126:104085

TITLE: Preparation of benzoic acid derivatives as 5-HT4 receptor agonists

INVENTOR(S): Suzuki, Takeshi; Iwaoka, Kyoshi; Naito, Makoto; Myata, Keiji; Kamato, Takeshi; Oota, Mitsuaki

PATENT ASSIGNEE(S): Yamanouchi Pharma Co Ltd, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 25 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08325234	A2	19961210	JP 1995-131264	19950530
PRIORITY APPLN. INFO.:			JP 1995-131264	19950530

OTHER SOURCE(S): MARPAT 126:104085

GI For diagram(s), see printed CA Issue.

AB The title compds. (Ia and Ib; Im = imidazolyl ring; A ring = 4-8 numbered cycloalkyl; n = 0-2; R2, R5, R6 = H, alkyl; B ring = 4-8 numbered N-contg. heterocyclyl; R3 = halo; R4 = lower alkoxy) are prepd. I, possessing 5-HT4 receptor antagonism, are useful for prevention and treatment of central and peripheral nervous system, digestive system, cardiovascular system, and urinary system diseases. Thus, 6-(tert-butoxycarbonylamino)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine was treated with aq. HCl to give the title compd. 6-amino-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine. I showed 5-HT4 receptor antagonism.

IT **185796-85-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzoic acid derivs. as 5-HT4 receptor agonists)


RN 185796-85-4 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine, 5-(4-amino-5-chloro-2-methoxybenzoyl)-4,5,6,7-tetrahydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 185796-84-3

CMF C14 H15 Cl N4 O2



CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



~~114~~ ANSWER 11 OF 25 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:436546 CAPLUS

DOCUMENT NUMBER: 125:221700

TITLE: Solid phase synthesis of tetrahydroisoquinolines and tetrahydroimidazopyridines

AUTHOR(S): Hutchins, Steven M.; Chapman, Kevin T.

CORPORATE SOURCE: Dep. Mol. Design Diversity, Merck Res. Lab., Rahway, NJ, 07065, USA

SOURCE: Tetrahedron Letters (1996), 37(28), 4865-4868

CODEN: TELEAY; ISSN: 0040-4039

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 125:221700

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The prepn. of 1,2,3,4-tetrahydroisoquinolines I (R1 = Me, Et, CO2Me, R2 = H, Me, OH) and II (R3 = Ph, 2-MeC6H4, 4-O2NC6H4, 2-furyl, etc.) and 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridines III (R1 = H, CO2Me) on a solid support has been developed. The route utilizes substituted m-tyramines, histamines and various arom., aliph. and heterocyclic aldehydes.

IT 181184-56-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(solid phase synthesis of tetrahydroisoquinolines and
-imidazopyridines)

RN 181184-56-5 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-acetamide, N-(2-amino-2-oxoethyl)-1,4,6,7-tetrahydro-4-(2-methylphenyl)-N-propyl- (9CI) (CA INDEX NAME)



~~L14~~ ANSWER 12 OF 25 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:721205 CAPLUS

DOCUMENT NUMBER: 123:111747

TITLE: Preparation of antibacterial 1-methylcarbapenem derivatives

INVENTOR(S): Oida, Sadao; Tanaka, Teruo; Konosu, Toshuki; Mori, Makoto; Myaoka, Takeo; Tajima, Kazu

PATENT ASSIGNEE(S): Sankyo Co, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 55 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07101959	A2	19950418	JP 1993-244299	19930930
PRIORITY APPLN. INFO.:			JP 1993-244299	19930930
OTHER SOURCE(S):		MARPAT 123:111747		

GI



AB Title compds. I [R1 = H, protecting group; R2 = H, protecting group, alkyl, alkenyl, C(:NR3); R3 = H, protecting group; R4 = H, alkyl, amino; A = cyclic substituent], useful as antibacterials (no data), are prepd. Thus, (2S,4S)-4-acetylthio-1-(4-nitrobenzyloxycarbonyl)-2-[(1S,4S)-5-(4-nitrobenzyloxycarbonyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]carbonylpyrrolidine (prepn. given) was treated with NaOMe in MeOH-THF and the product was reacted with (1R,5R,6S)-6-[(R)-1-hydroxyethyl]-1-methyl-2-(diphenylphosphoryloxy)carbapenem-3-carboxylic acid 4-nitrobenzyl ester in MeCN contg. diisopropylethylamine to give (1R,5S,6S)-6-(R)-1-hydroxyethyl-1-methyl-2-[(2S,4S)-1-(4-nitrobenzyloxycarbonyl)-2-[(2S,4S)-5-(4-nitrobenzyloxycarbonyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]carbonyl]pyrrolidin-4-yl]thio]carbapenem-3-carboxylic acid 4-nitrobenzyl ester. Pharmaceutical compns. contg. I are described.

IT 165893-60-7P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);


BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
USES (Uses)

(prepn. of antibacterial 1-methylcarbapenem derivs.)

RN 165893-60-7 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-4-methyl-3-[[1-[[[4-nitrophenyl)methoxy]carbonyl]-5-[(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)carbonyl]-3-pyrrolidinyl]thio]-7-oxo-, (4-nitrophenyl)methyl ester, [4R-[3(3S*,5S*),4.alpha.,5.beta.,6.beta.(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 165893-88-9P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of antibacterial 1-methylcarbapenem derivs.)

RN 165893-88-9 CAPLUS


CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-4-methyl-7-oxo-3-[[5-[(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)carbonyl]-3-pyrrolidinyl]thio]-, monohydrochloride, [4R-[3(3S*,5S*),4.alpha.,5.beta.,6.beta.(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




HCl


L14 ANSWER 13 OF 25 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1990:216653 CAPLUS
DOCUMENT NUMBER: 112:216653
TITLE: Synthesis of 6-aryl-4,5-dibenzamido-1,2,3,6-tetrahydropyridines
AUTHOR(S): Stocker, Fred B.; Evans, April J.
CORPORATE SOURCE: Dep. Chem., Macalester Coll., St. Paul, MN, 55105, USA
SOURCE: Journal of Organic Chemistry (1990), 55(10), 3370-3
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 112:216653
GI




AB Bamberger reaction of 4-aryltetrahydroimidazo[4,5-c]pyridines I (R = Me, OMe, Cl; R1 = H) gave predominately I (R1 = CH₂Ph) with only small amts. of title compds. II (R1 = CH₂Ph). Reaction of I (R1 = Me), however, gave II (R1 = Me) in 65-68% yield.
IT **126036-49-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 126036-49-5 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine, 5-benzoyl-4,5,6,7-tetrahydro-4-(4-methylphenyl)-(9CI) (CA INDEX NAME)



L14 ANSWER 14 OF 25 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1985:105733 CAPLUS
DOCUMENT NUMBER: 102:105733
TITLE: Anti-ulcer and antisecretory activity of selected imidazopiperidines
AUTHOR(S): Arcari, G.; Bernardi, L.; Cimaschi, R.; Falconi, G.; Luini, F.; Scarponi, U.
CORPORATE SOURCE: Farmitalia Carlo Erba S.p.A., Milan, I-20146, Italy
SOURCE: Arzneimittelforschung (1984), 34(11), 1467-71
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II


AB New thioureas and ureas, 4,5,6,7-tetrahydroimidazo[4,5-c]pyridine derivs. I and II (X = S, O) with antiulcer and antisecretory activities, were synthesized, and their structure-activity relations examd. For I and II (R1 = R2 = H and X = S), a low level of antiulcer activity was obsd. when R3 is a cyclohexyl, Ph, or alkyl. Reducing the ring size (R3 = cyclopentyl, cyclopropyl) or shortening the chain (R3 = Me) improved the activity. The highest antiulcer activity combined with the highest antisecretory activity was obsd. when R3 = CHMe2. When X = S, R1 = H, and R3 = CHMe2, the introduction of a substituent in position 4 was detrimental for the potency, notably when R2 was a Ph, a heterocyclic, or branched alkyl. A still good level of antiulcer activity was obsd. only when R2 was Et. The Me and Pr derivs. showed good antiulcer activity, with the 1-substituted derivs. showing the higher potency. When X = O, a good antiulcer activity and reasonable level of antisecretory activity were obsd.

IT **70651-72-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and alkylation of)

RN 70651-72-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT **70651-74-0P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and amidation and deprotection of)

RN 70651-74-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 3,4-diethyl-3,4,6,7-tetrahydro-, phenylmethyl ester (9CI) (CA INDEX NAME)



114 ANSWER 15 OF 25 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1983:470725 CAPLUS

DOCUMENT NUMBER: 99:70725

TITLE: 1- or 1,3-Substituted 4,5,6,7-tetrahydroimidazo[4,5-c]pyridines

INVENTOR(S): Yutilov, Yu. M.; Eilazyan, O. G.

PATENT ASSIGNEE(S): Institute of Physical-Organic Chemistry and Coal Chemistry, Academy of Sciences, Ukrainian S.S.R., USSR U.S.S.R. From: Otkrytiya, Izobret., Prom. Obratzsy, Tovarnye Znaki 1983, (10), 106.

SOURCE: U.S.S.R. From: Otkrytiya, Izobret., Prom. Obratzsy, Tovarnye Znaki 1983, (10), 106.

CODEN: URXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Russian


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
SU 1004385	A1	19830315	SU 1981-3258836	19810309
PRIORITY APPLN. INFO.:			SU 1981-3258836	19810309
OTHER SOURCE(S):		CASREACT 99:70725		
GI				



I



II


AB Title compds. I (R = Me, Et; R1 = H, Me) are prepd. by a simplified procedure with increased yield and expanded scope by treating methoxy-substituted 5-(.beta.-phenyl-.beta.-hydroxyethyl)-4,5,6,7-tetrahydroimidazo[4,5-c]pyridines II (same R, R1; R2 = H, OMe) with HCl in refluxing aq. alc.

IT 86674-44-4D, derivs.


RL: RCT (Reactant); RACT (Reactant or reagent) (hydrolysis of)

RN 86674-44-4 CAPLUS


CN 5H-Imidazo[4,5-c]pyridine-5-ethanol, 1,4,6,7-tetrahydro-.alpha.-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




L14 ANSWER 16 OF 25 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1981:569075 CAPLUS
DOCUMENT NUMBER: 95:169075
TITLE: New synthesis of spinaceamine derivatives
AUTHOR(S): Yutilov, Yu. M.; Eilazyan, O. G.
CORPORATE SOURCE: Inst. Fiz.-Org. Khim. Uglekhim., Donetsk, 340048, USSR
SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1981), (7),
992
CODEN: KGSSAQ; ISSN: 0453-8234
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI



AB Spinaceamine derivs. I (R = Et, CH₂CH₂OH), II (R = Me, benzyl, CH₂CH₂OH) and III were prepd. in 69-98% yield by redn. of quaternary salts of 1- and 3-substituted imidazo[4,5-c]pyridine with NaBH₄ or KBH₄ in aq. or alc. soln. at room temp.
IT **79457-28-6P 79457-30-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 79457-28-6 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-ethanol, 3,4,6,7-tetrahydro-3-methyl-, compd. with 2,4,6-trinitrophenol (9CI) (CA INDEX NAME)
CM 1
CRN 79457-27-5
CMF C9 H15 N3 O




CM 2
CRN 88-89-1
CMF C6 H3 N3 O7



RN 79457-30-0 CAPLUS
CN 3H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-3-methyl-5-(phenylmethyl)-, compd. with 2,4,6-trinitrophenol (9CI) (CA INDEX NAME)


CM 1

CRN 79457-29-7
CMF C14 H17 N3



CM 2


CRN 88-89-1
CMF C6 H3 N3 O7




L14 ANSWER 17 OF 25 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1979:439486 CAPLUS
DOCUMENT NUMBER: 91:39486
TITLE: 4,5,6,7-Tetrahydroimidazo[4,5-c]pyridine derivatives
INVENTOR(S): Arcari, Guiliana; Bernardi, Luigi; Falconi, Giovanni;
Scarponi, Ugo
PATENT ASSIGNEE(S): Societa Farmaceutici Italia S.p.A., Italy
SOURCE: Belg., 18 pp.
CODEN: BEXXAL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 871985	A1	19790301	BE 1978-191705	19781114
NL 7811125	A	19800211	NL 1978-11125	19781109
NL 181657	B	19870504		
NL 181657	C	19871001		
AU 7841490	A1	19800214	AU 1978-41490	19781110

AU 520102	B2	19820114		
CA 1113468	A1	19811201	CA 1978-316132	19781110
CH 636875	A	19830630	CH 1978-11596	19781110
AT 7808117	A	19791215	AT 1978-8117	19781113
AT 357533	B	19800710		
DK 7805026	A	19800208	DK 1978-5026	19781113
DK 146159	B	19830711		
DK 146159	C	19831205		
FR 2433022	A1	19800307	FR 1978-31960	19781113
FR 2433022	B1	19810612		
GB 2028798	A	19800312	GB 1978-44281	19781113
GB 2028798	B2	19820811		
US 4223146	A	19800916	US 1978-959506	19781113
ZA 7806388	A	19791031	ZA 1978-6388	19781114
SE 7811761	A	19800208	SE 1978-11761	19781114
SE 438150	B	19850401		
SE 438150	C	19850711		
JP 55024158	A2	19800221	JP 1978-139477	19781114
JP 58010387	B4	19830225		
DE 2849572	A1	19800221	DE 1978-2849572	19781115
DE 2849572	C2	19860626		
SU 791241	D	19801223	SU 1978-2685600	19781115
PRIORITY APPLN. INFO.:			IT 1978-26562	19780807
GI				



I



II


AB Thiocarbamoylimidazopyridines I (R = C1-4 alkyl; R₁ = H, C1-4 alkyl; R₂ = C1-4 aliph.) were prepd. Thus, II (R = R₃ = H) was treated with ClCO₂CH₂Ph and EtBr to give II (R = Et, R₃ = CO₂CH₂Ph), which was treated with HBr to give II (R = Et, R₃ = H). Treatment of the latter compd. with Me₂CHNCO gave I (R = R₁ = Et, R₂ = CHMe₂), which had an antiulcer ED₅₀ of 3.5 mg/kg orally in rats with little anticholinergic activity.

IT 70651-72-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and alkylation of)

RN 70651-72-8 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



Same as previous


● HCl

IT 70651-74-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 70651-74-0 CAPLUS

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 3,4-diethyl-3,4,6,7-tetrahydro-, phenylmethyl ester (9CI) (CA INDEX NAME)



L14 ANSWER 18 OF 25 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1968:87234 CAPLUS

DOCUMENT NUMBER: 68:87234

TITLE: Synthetic spinaceamines

AUTHOR(S): Vitali, Tullo; Mossini, Ferdinando; Bertaccini, Giulio

CORPORATE SOURCE: Univ. Parma, Parma, Italy

SOURCE: Farmaco, Edizione Scientifica (1967), 22(10), 821-45

CODEN: FRPSAX; ISSN: 0430-0920

DOCUMENT TYPE: Journal

LANGUAGE: Italian

GI For diagram(s), see printed CA Issue.

AB Histamine is treated with aldehydes and ketones to give I and II. Thus, a soln. of 0.01 mole histamine in 10 ml. MeOH is treated with 1.6 g. NaOH in 3 ml. water and 0.04 mole Me₂CO in 27 ml. MeOH; the mixt. is heated 10-24 hrs. to give 80% 5,5-dimethylspinaceamine (III), m. 188-9.degree. (EtOH), dihydrochloride hydrate m. 253-4.degree. (EtOH-C₆H₆), dipicrate dihydrate m. 236-7.degree. (water). Similarly prepd. are the following I (X = Y = H) (R, R1, m.p., m.p. dipicrate, % yield, and salt m.p. given): Me, Et, -, -, -, HCl 244-6.degree. (decompn.) (EtOH); Me, Ph, -, -, -, 2HCl 240-2.degree. (EtOH), dipicrate dihydrate 212-13.degree. (aq. EtOH); Et, Ph, -, 197-8.degree. (aq. EtOH), -, 2HCl 228-30.degree. (EtOH); Me, 2-furyl, -, 168-9.degree. (EtOH), -, H₂O 115-16.degree. (water); Me, 2-thienyl, -, -, -, H₂O 116-18.degree. (water); H, tert-Bu, 166-7.degree. (water), -, 85, dipicrate hydrate 206-7.degree. (water); H, Ph, 201-2.degree. (water), -, 95, 2HCl.1/2H₂O 252-4.degree. (EtOH), 2HNO₃ 207-9.degree. (EtOH), dipicrate hydrate 221-2.degree. (aq. EtOH); H, PhCH₂, -, -, -, 2HCl.H₂O 149-50.degree. (decompn.) (EtOH), dipicrate hydrate 148-50.degree. (aq. EtOH); H, o-ClC₆H₄, 204-5.degree., -, 95, dipicrate hydrate 256.degree. (decompn.) (EtOH); H, m-ClC₆H₄, 178-9.degree. (water), -, 95, dipicrate hydrate 203-4.degree. (EtOH); H, p-ClC₆H₄, 179-80.degree., -, 95, dipicrate hydrate 222-3.degree. (EtOH); H, m-tolyl, -, 279-80.degree. (EtOH), -, 1/2H₂O 169-70.degree. (water); H,


p-tolyl, 177-8.degree. (water), 228.degree. (EtOH), 95, -; H, o-O₂NC₆H₄, 216-17.degree. (decompn.) (water), 220-1.degree. (EtOH), 80, -; H, m-O₂NC₆H₄, -, 281-2.degree. (EtOH), -, 1/2H₂O 177-8.degree. (water); H, p-O₂NC₆H₄, 235-6.degree. (decompn.) (water), 178-80.degree. (water), 80, -; H, p-Me₂NC₆H₄, -, -, -, H₂O 186-7.degree. (water); H, o-MeOC₆H₄, -, 243-4.degree. (EtOH), -, H₂O 129-30.degree. (water), 2HCl.H₂O 257-8.degree. (EtOH); H, m-MeOC₆H₄, 158-9.degree. (water), -, 75, dipicrate hydrate 228-9.degree. (EtOH); H, p-MeOC₆H₄, 186-7.degree. (water), -, 80, dipicrate hydrate 221-2.degree. (aq. EtOH); H, 3,4-(MeO)₂C₆H₃, -, 233.degree. (aq. EtOH), -, 2HCl.1/2H₂O 140-1.degree. (decompn.) (EtOH); H, 3,4,5-(MeO)₃C₆H₂, 155-6.degree. (water), -, 80, picrate hydrate 165-6.degree. (aq. EtOH); H, 3,4-(CH₂O₂)C₆H₃, 187-8.degree. (water), 217-18.degree. (EtOH), 85, -; H, 2-methyl-3-hydroxy-5-hydroxy-methyl-4-pyridyl, 252.degree. (decompn.) (water), 234.degree. (decompn.) (EtOH), 90, -; RR1 = (CH₂)₅, -, -, -, -, 1/4H₂O 210-11.degree. (water); RR1 = (CH₂)₄, -, -, -, -, 1/2H₂O 161-2.degree. (water). N.M.R. data for III and I (X = Y = R = H, R1 = Ph) are given; uv and chromatographic data for the prepd. compds. are also given. Histamine is treated with an equimolar amt. of p-MeOC₆H₄CHO at a low temp. to give 80% N',N'-(p-methoxybenzylidene)histamine, m. 111-13.degree. (C₆H₆). Similarly prepd. are the following II (R = H) (R1, m.p., and % yield given): p-ClC₆H₄, 125-7.degree. (C₆H₆), 98; p-HOC₆H₄, 162-4.degree. (EtOH-ether), 78; uv data for the prepd. II are given. A soln. of 2.5 g. III-2HCl in water is treated with 4.2 g. BzCl in the presence of 2.5 g. NaOH (10% soln.) to give .apprx.1.2 g. I (X = Y = Bz, R = R1 = Me), m. 223-4.degree. (aq. EtOH). Similarly prepd. is I (X = R = H, R1 = Ph, Y = Ac), m. 194-5.degree. (water). A mixt. of 2.0 g. III, 2.5 g. H₂CO (35%), and 5.0 g. HCO₂H (85%) is refluxed 5 hrs. to give I (X = H, R = R1 = Y = Me), m. 143-3.5.degree. (Me₂CO), 2HCl salt m. 242-6.degree. (alc.-Me₂CO), dipicrate m. 229.5-30.5.degree. (decompn.) (water). A soln. of 3 g. I (R = X = Y = H, R1 = Ph) in 12 ml. concd. H₂SO₄ is treated at 5-10.degree. with 1.0 ml. fuming HNO₃ to give 2.5 g. I (R = X = Y = H, R1 = m-O₂NC₆H₄) (IV), m. 175-6.degree. (aq. alc.). IV (0.5 g.) in 16 ml. water contg. 0.5 g. KOH is treated with satd. KMnO₄ to give m-O₂NC₆H₄CO₂H, m. 139-40.degree. (water). IV (4.0 g.) is treated with 7 g. Sn and 14 ml. HCl to give I (R = X = Y = H, R1 = m-H₂NC₆H₄) (V), picrate m. 178-80.degree. (decompn.) (water). V is diazotized at 0.degree. with 1.2 g. NaNO₂ and 6.5 ml. concd. HCl and the product is heated with 8.0 g. Cu₂Cl₂ in 23 ml. concd. HCl to give I (R = X = Y = H, R1 = m-ClC₆H₄), m. 177-8.degree. (water). A soln. prepd. from 1.0 g. I (X = R = H, R1 = Ph, Y = Ac), 2.0 g. concd. H₂SO₄, and 0.6 g. HOAc is treated at 5-10.degree. with 0.3 g. fuming HNO₃ and 0.3 g. concd. H₂SO₄ to give I (X = R = H, R1 = m-O₂NC₆H₄, Y = Ac), m. 218-19.degree. (water), which is treated with 20% HCl to give IV, m. 177-8.degree..

IT **18096-47-4P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 18096-47-4 CAPLUS

CN 3H-Imidazo[4,5-c]pyridine, 3,5-dibenzoyl-4,5,6,7-tetrahydro-4,4-dimethyl-
(8CI) (CA INDEX NAME)



ACCESSION NUMBER: 2002:344459 USPATFULL
TITLE: New use
INVENTOR(S): Besencon, Olivier, Allschwil, SWITZERLAND
Olsson, Rolf, Gnesta, SWEDEN
Ohman, Johan, Uppsala, SWEDEN
Caldirola, Patrizia, Uppsala, SWEDEN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002198189	A1	20021226
APPLICATION INFO.:	US 2001-45319	A1	20011109 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	SE 2000-4101	20001109
	US 2000-252156P	20001120 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JEFFREY D. HSI, Fish & Richardson P.c., 225 Franklin Street, Boston, MA, 02110-2804	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1754	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treatment or prophylaxis of SSAO-mediated complications in mammals including humans, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of Formula (I): ##STR1##

in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as described in the specification.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 424837-38-7P, Benzyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate 424837-55-8P, 4-Phenyl-5-(phenoxyacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine trifluoroacetate
(drug candidate; prepn. of tetrahydroimidazopyridine derivs. as SSAO inhibitors for treatment of diabetic complications)
RN 424837-38-7 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, phenylmethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 424837-37-6
CMF C16 H19 N3 O2

Same as ref 14.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 424837-55-8 USPATFULL
CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-(phenoxyacetyl)-4-phenyl-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 424837-54-7
CMF C20 H19 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




IT 424837-36-5P, Methyl 4-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-40-1P, Benzyl 4-phenyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate 424837-41-2P, Benzyl 4-benzyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-43-4P, Benzyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate 424837-45-6P, Methyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate 424837-47-8P, Methyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate 424837-49-0P, Methyl 4-phenyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate 424837-51-4P, 4-Ethyl-5-(phenoxyacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine trifluoroacetate 424837-53-6P, 4-Propyl-5-(phenoxyacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine trifluoroacetate 424837-57-0P, Cyclopentyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate 424837-59-2P, Cyclopentyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate 424837-61-6P, Cyclopentyl 4-phenyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate 424837-63-8P, 4-Fluorophenyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate

424837-65-0P, 4-Fluorophenyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate
424837-66-1P, 2-Methoxyethyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-67-2P,
2-Methoxyethyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-68-3P, 2-Methoxyethyl 4-phenyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-69-4P
, Benzyl 4-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-70-7P, 4-Methyl-5-(phenoxyacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine 424837-71-8P, Allyl 4-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-72-9P, Allyl 4-ethyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-73-0P, Allyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-74-1P, 2,2,2-Trichloroethyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-75-2P, Allyl 4-benzyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-76-3P, 2,2,2-Trichloroethyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-77-4P, 2,2,2-Trichloroethyl 4-benzyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-78-5P, 4-Nitrobenzyl 4-ethyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-79-6P, 4-Nitrobenzyl 4-propyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 424837-85-4P, 4-Fluorophenyl 4-phenyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate trifluoroacetate

(drug candidate; prepn. of tetrahydroimidazopyridine derivs. as SSAO inhibitors for treatment of diabetic complications)

RN 424837-36-5 USPATFULL

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 424837-40-1 USPATFULL

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-phenyl-, phenylmethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-39-8


CMF C20 H19 N3 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 424837-41-2 USPATFULL

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 424837-43-4 USPATFULL

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-, phenylmethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-42-3


CMF C17 H21 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 424837-45-6 USPATFULL

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-44-5


CMF C10 H15 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 424837-47-8 USPATFULL

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-46-7


CMF C11 H17 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 424837-49-0 USPATFULL

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-phenyl-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-48-9


CMF C14 H15 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 424837-51-4 USPATFULL

CN 1H-Imidazo[4,5-c]pyridine, 4-ethyl-4,5,6,7-tetrahydro-5-(phenoxyacetyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-50-3


CMF C16 H19 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 424837-53-6 USPATFULL

CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-5-(phenoxyacetyl)-4-propyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 424837-52-5
CMF C17 H21 N3 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 424837-57-0 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-,
cyclopentyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 424837-56-9
CMF C14 H21 N3 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 424837-59-2 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-,
cyclopentyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 424837-58-1
CMF C15 H23 N3 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 424837-61-6 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-phenyl-,
cyclopentyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 424837-60-5
CMF C18 H21 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 424837-63-8 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-,
4-fluorophenyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-62-7


CMF C15 H16 F N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 424837-65-0 USPATFULL

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-,
4-fluorophenyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-64-9


CMF C16 H18 F N3 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 424837-66-1 USPATFULL


CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-,
2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 424837-67-2 USPATFULL

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-,
2-methoxyethyl ester (9CI) (CA INDEX NAME)


RN 424837-68-3 USPATFULL

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-phenyl-,
2-methoxyethyl ester (9CI) (CA INDEX NAME)

RN 424837-69-4 USPATFULL


CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-methyl-,
phenylmethyl ester (9CI) (CA INDEX NAME)

RN 424837-70-7 USPATFULL

CN 1H-Imidazo[4,5-c]pyridine, 4,5,6,7-tetrahydro-4-methyl-5-(phenoxyacetyl)-
(9CI) (CA INDEX NAME)


RN 424837-71-8 USPATFULL

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-methyl-,
2-propenyl ester (9CI) (CA INDEX NAME)




RN 424837-72-9 USPATFULL

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-,
2-propenyl ester (9CI) (CA INDEX NAME)




RN 424837-73-0 USPATFULL

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-,
2-propenyl ester (9CI) (CA INDEX NAME)




RN 424837-74-1 USPATFULL

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-,
2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)




RN 424837-75-2 USPATFULL


CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-(
phenylmethyl)-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 424837-76-3 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-,
2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)




RN 424837-77-4 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-(phenylmethyl)-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)



RN 424837-78-5 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-,
(4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)



RN 424837-79-6 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-propyl-,
(4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)




RN 424837-85-4 USPATFULL
CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 1,4,6,7-tetrahydro-4-phenyl-,
4-fluorophenyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 424837-84-3


CMF C19 H16 F N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L14 ANSWER 20 OF 25 USPATFULL

ACCESSION NUMBER: 2002:340381 USPATFULL

TITLE: Tetrahydrobenzindole derivatives

INVENTOR(S): Kikuchi, Chika, Kanagawa, JAPAN

Ando, Takashi, Kanagawa, JAPAN

Fuji, Kazuyuki, Kanagawa, JAPAN

Okuno, Masayo, Kanagawa, JAPAN

Morita, Eriko, Kanagawa, JAPAN

Imai, Masako, Kanagawa, JAPAN

Ushiroda, Osamu, Kanagawa, JAPAN

Koyama, Masao, Kanagawa, JAPAN

Hiranuma, Toyokazu, Kanagawa, JAPAN

PATENT ASSIGNEE(S): Meiji Seika Kaisha, Ltd., Tokyo, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6498251	B1	20021224
	WO 9933804		19990807
APPLICATION INFO.:	US 2001-582416		20010308 (9)
	WO 1998-JP5827		19981222

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-358380	19971225
	JP 1997-358381	19971225
	JP 1998-85913	19980331
	JP 1998-136872	19980519
	JP 1998-229709	19980814
	JP 1998-319336	19981110

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Shah, Mukund J.

ASSISTANT EXAMINER: Liu, Hong

LEGAL REPRESENTATIVE: Sughrue Mion, PLLC

NUMBER OF CLAIMS: 12

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)

LINE COUNT: 4170

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds containing tetrahydrobenzindole which bind to serotonin receptor and are useful in treatment or prevention of disease induced by abnormality of central peripheral serotonin controlling functions.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 230301-50-5P 230301-52-7P

(tetrahydrobenzindole derivs. for treatment and prevention of diseases caused by abnormality in serotonin regulatory system)


RN 230301-50-5 USPATFULL

CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butyl]- (9CI) (CA INDEX NAME)



RN 230301-52-7 USPATFULL

CN Benz[cd]indol-2(1H)-one, 2a,3,4,5-tetrahydro-2a-[4-(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L14 . ANSWER 21 OF 25 USPATFULL

ACCESSION NUMBER: 2002:39930 USPATFULL

TITLE: Inhibitors of prenyl-protein transferase

INVENTOR(S): deSolms, S. Jane, Collegeville, PA, United States

Shaw, Anthony W., Lansdale, PA, United States

PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6350755	B1	20020226
APPLICATION INFO.:	US 2001-757218		20010109 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-175703P	20000112 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Kifle, Bruck	
LEGAL REPRESENTATIVE:	Muthard, David A., Daniel, Mark R.	
NUMBER OF CLAIMS:	18	

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3178
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to peptidomimetic macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 350687-92-2P 350687-93-3P

(macrocyclic peptidomimetic inhibitors of prenyl-protein transferase for inhibiting prenylation of Ras oncoprotein)


RN 350687-92-2 USPATFULL

CN 3H-Imidazo[4,5-c]pyridine, 4-(4-cyano-3-fluorophenyl)-4,5,6,7-tetrahydro-5-[3-[[(3-methoxyphenyl)sulfonyl]amino]-1-oxopropyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 350687-93-3 USPATFULL

CN 3H-Imidazo[4,5-c]pyridine, 4-(4-cyano-3-fluorophenyl)-4,5,6,7-tetrahydro-5-[3-[[(3-hydroxyphenyl)sulfonyl]amino]-1-oxopropyl]-3-methyl- (9CI) (CA INDEX NAME)



L14 ANSWER 22 OF 25 USPATFULL

ACCESSION NUMBER: 2002:13995 USPATFULL

TITLE: 4,4-difluoro-2,3,4,5-tetrahydro-1H-1-benzoazepine derivatives and drug compositions containing them

INVENTOR(S): Matsuhisa, Akira, Ushiku, JAPAN

Murakami, Takeshi, Tsukuba, JAPAN

Sakuda, Shuichi, Tokyo, JAPAN

Kawano, Noriyuki, Tsukuba, JAPAN

Shibasaki, Kumiko, Tsukuba, JAPAN

Tanaka, Akihiro, Tsuchiura, JAPAN

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Tokyo, JAPAN

(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6340678	B1	20020122
	WO 9839325		19980911
APPLICATION INFO.:	US 1999-380683		19990902 (9)
	WO 1998-JP916		19980305
			19990902 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-52163	19970306
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Coleman, Brenda	
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett & Dunner, LLP	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	2188	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 4,4-difluoro-2,3,4,5-tetrahydro-1H-1-benzazepine compounds or salts thereof and pharmaceutical compositions containing 4,4-difluoro-2,3,4,5-tetrahydro-1H-1-benzazepine compounds, or salts thereof, and a pharmaceutically acceptable carrier. The chemical structure of these compounds is characterized by a difluoro group on a ring carbon atom adjacent to an azepine ring carbon atom substituted with a methyldiene group. Pharmaceutical compositions containing these compounds are particularly useful as oxytocin antagonists and are effective in inhibiting threatened premature birth or abortion and precesarean birth, and are effective as a remedy for dysmenorrhea and other such conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 213021-71-7P

(prepn. of difluorotetrahydrobenzazepine derivs. as oxytocin antagonists)

RN 213021-71-7 USPATFULL

CN 1H-1-Benzazepine, 4,4-difluoro-2,3,4,5-tetrahydro-1-[(4-methyl-2-phenyl-5-thiazolyl)carbonyl]-5-[2-oxo-2-(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethylidene]-, monohydrochloride, (5Z)-(9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



● HCl

L14 ANSWER 23 OF 25 USPATFULL

ACCESSION NUMBER: 2000:77368 USPATFULL
TITLE: Inhibitors of farnesyl-protein transferase
INVENTOR(S): Graham, Samuel L., Schwenksville, PA, United States
Young, Steven D., Lansdale, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6077853		20000620
APPLICATION INFO.:	US 1999-300910		19990428 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-995744, filed on 22 Dec 1997, now patented, Pat. No. US 5939439, issued on 17 Aug 1999		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Fan, Jane		
LEGAL REPRESENTATIVE:	Muthard, David A., Daniel, Mark R.		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
LINE COUNT:	4987		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 210037-52-8P 210037-53-9P

(prepn. of oxypyridinylmethylimidazolylmethylbenzonitriles and related compds. as inhibitors of farnesyl-protein transferase)


RN 210037-52-8 USPATFULL

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-(4-cyanophenyl)-1,4,6,7-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 210037-53-9 USPATFULL

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 3-[(5-chloro-2-oxo[1(2H),2'-bipyridin]-5'-yl)methyl]-4-(4-cyanophenyl)-3,4,6,7-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L14 ANSWER 24 OF 25 USPATFULL

ACCESSION NUMBER: 1999:96390 USPATFULL

TITLE: Inhibitors of farnesyl-protein transferase

INVENTOR(S): Anthony, Neville J., Hatfield, PA, United States

Graham, Samuel L., Schwenksville, PA, United States

Tran, Lekhanh O., Norristown, PA, United States

Bell, Ian M., Harleysville, PA, United States

deSolms, S. Jane, Norristown, PA, United States

Gomez, Robert P., Perkasio, PA, United States

Kuo, Michelle Sparks, Gwynedd Valley, PA, United States

Lumma, Jr., William C., Pennsburg, PA, United States

Perlow, Debra S., East Greenville, PA, United States

Shaw, Anthony W., Lansdale, PA, United States

Wai, John S., Harleysville, PA, United States

Young, Steven D., Lansdale, PA, United States

PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5939439		19990817
APPLICATION INFO.:	US 1997-995744		19971222 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-33990P	19961230 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Fan, Jane	
LEGAL REPRESENTATIVE:	Muthard, David A., Daniel, Mark R.	
NUMBER OF CLAIMS:	21	

EXEMPLARY CLAIM: 1
LINE COUNT: 4949

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 210037-52-8P 210037-53-9P

(prepn. of oxopyridinylmethylimidazolylmethylbenzonitriles and related compds. as inhibitors of farnesyl-protein transferase)


RN 210037-52-8 USPATFULL

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-(4-cyanophenyl)-1,4,6,7-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 210037-53-9 USPATFULL

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 3-[(5-chloro-2-oxo[1(2H),2'-bipyridin]-5'-yl)methyl]-4-(4-cyanophenyl)-3,4,6,7-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L14 ANSWER 25 OF 25 USPATFULL

ACCESSION NUMBER: 80:45756 USPATFULL

TITLE: 4,5,6,7-Tetrahydroimidazo-[4,5-c]-pyridine derivatives

INVENTOR(S): Arcari, Giuliana, Milan, Italy

Bernardi, Luigi, Milan, Italy

Falconi, Giovanni, Milan, Italy

Scarponi, Ugo, Milan, Italy

PATENT ASSIGNEE(S): Farmitalia Carlo Erba S.p.A., Milan, Italy (non-U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 4223146 19800916
APPLICATION INFO.: US 1978-959506 19781113 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1978-26562	19780807
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Rotman, Alan L.	
ASSISTANT EXAMINER:	Harkaway, Natalia	
LEGAL REPRESENTATIVE:	Stevens, Davis, Miller & Mosher	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
LINE COUNT:	360	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds are disclosed of the general formula (I): ##STR1## wherein R.sub.1 is a lower alkyl having from 1 to 4 carbon atoms; R.sub.2 is hydrogen or a lower alkyl having from 1 to 4 carbon atoms; and R.sub.3 is a saturated or unsaturated straight or branched alkyl having from 1 to 4 carbon atoms. A process for making such compounds is also disclosed. These compounds are useful as antiulcer agents and as inhibitors of gastric secretion.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 70651-72-8P

(prepn. and alkylation of)

RN 70651-72-8 USPATFULL

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 4-ethyl-1,4,6,7-tetrahydro-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 70651-74-0P

(prepn. of)

RN 70651-74-0 USPATFULL

CN 5H-Imidazo[4,5-c]pyridine-5-carboxylic acid, 3,4-diethyl-3,4,6,7-tetrahydro-, phenylmethyl ester (9CI) (CA INDEX NAME)



FILE 'CAOLD' ENTERED AT 10:46:40 ON 24 FEB 2003

Searched by Barb O'Bryen, STIC 308-4291

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L1	STR
L3	STR
L4	STR
L6	585 SEA FILE=REGISTRY SSS FUL L1 NOT (L3 OR L4)
L8	STR
L10	165 SEA FILE=REGISTRY SUB=L6 SSS FUL L8
L13	0 SEA FILE=CAOLD ABB=ON L10

FILE 'HOME' ENTERED AT 10:46:40 ON 24 FEB 2003

THIS PAGE BLANK (USPTO)